Use of antiepileptic drugs in pregnancy

Expert Review of Neurotherapeutics

Volumn 6, Issue 7, 2006, Pages 1077-1086

  Tatum, William O ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Antiepileptic drugs; Birth defects; Malformations; Pregnancy; Teratogenesis

Indexed keywords

BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GABATRIL; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

BIRTH DEFECT; DOSE RESPONSE; DRUG SAFETY; EPILEPSY; HUMAN; MENTAL DISEASE; PREGNANCY; REVIEW; SEIZURE; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; RISK FACTORS;

EID: 33745960460     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.7.1077     Document Type: Review

References (78)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 34, 453-468 (1993).
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Eng. J. Med. 342, 314-319 (2000).
3. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 55(Suppl. 1), S21-S31 (2000).
4. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurology 51, 944-948 (1998).
5. Lipton RB, Stewart WF, Diamond S, Diamond MI, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41, 646-657 (2001).
6. Eberhard-Gran M, Eskild A, Opjordsmoen S. Treating mood disorders during pregnancy: safety considerations. Drug Safety 28(8), 695-706 (2005).
7. Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 55(Suppl. 1), S41-S46 (2000).
8. Devinsky O, Yerby M. Women with epilepsy. Neurol. Clin. 12, 479-495 (1994).
9. Tatum IV WO, Liporace J, Benbadis SR, Kaplan PW. Updates on the treatment of epilepsy in women. Arch. Intern. Med. 164, 137-145 (2004).
10. Tatum IV WO, Galvez R, Benbadis SR, Carrazana E. New antiepileptic drugs: into the new millennium. Arch. Fam. Med. 9, 1135-1141 (2000).
11. Morrell MJ, Montouris GD. Reproductive disturbances in patients with epilepsy. Cleve Clin. J. Med. 7(Suppl. 2), S19-S24 (2004).
12. Karnard DR, Guntupalli KK. Neurologic disorders in pregnancy. Critical Care Medicine 33(Suppl. 10), S362-S371 (2005).
13. Kaplan PW. The neurologic consequences of eclampsia. The Neurologist 7(6), 357-363 (2001).
14. Laskowska M, Leszczynska-Gorzelak B, Oleszczuk J. Pregnancy in women with epilepsy. Gynecol. Obstet. Invest. 51(2), 99-102 (2001).
15. Kean LH, Gargari SS, Suwanrath C, Sahota DS, James DK. A comparison of fetal behavior in term fetuses exposed to anticonvulsant medication with unexposed controls. BJOG 108(11), 1159-1163 (2001).
16. Hvas CL, Henriksen TB, Ostergaard JR, Dam M. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birth weight. BJOG 107(7), 896-902 (2000).
17. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J. Clinical Neuroscience 10(5), 543-549 (2003).
18. Vajda FJ, O'Brien TJ, Hitchcock A et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of antiepileptic drugs in pregnancy. J. Clin. Neurosci. 11, 854-858 (2004).
19. Yerby MS. The use anticonvulsants during pregnancy. Semin. Perinatol. 25(3), 153-158 (2001).
20. Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. 344, 1132-1138 (2001).
21. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurology 4, 781-786 (2005).
22. Koch S, Losche G, Jager-Roman E et al. Major and minor birth malformations and antiepileptic drugs. Neurology 42(Suppl. 5), 83-88 (1992).
23. Fried S, Kozer E, Nulman E, Elinarson TR, Koren G. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Safety 45, 1171-1175 (2004).
24. Pennell PB. Pregnancy in women who have epilepsy. Neurol. Clin. 22, 799-820 (2004).
25. The EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP Epilepsy Pregnancy Register. Neurology 66, 354-360 (2006).
26. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 61(6 Suppl. 2), S35-S42 (2003).
27. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 20, 729-737 (1979).
28. Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA, Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64, 949-954 (2005).
29. Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst. Rev. 3, CD004848 (2004).
30. Richmond JR, Krishnamoorthy P, Andermann E, Benjamin A. Epilepsy and pregnancy: an obstetric perspective. Am. J. Ob. Gyn. 190(2), 371-379 (2004).
31. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 46(Suppl. 9), 117-124 (2005).
32. Beghi E, Annegers JF, Collaborative Group for the Pregnancy Registries in Epilepsy. Pregnancy registries in epilepsy. Epilepsia 42(11), 1142-1425 (2001).
33. Morrell M. Epilepsy and pregnancy: minimizing the risks. Contemp. Ob. Gyn. 49, 51-70 (2004).
34. Mawer G, Clayton-Smith J, Coyle H et al. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 11, 512-518 (2002).
35. Canger R, Battino D, Canevini MP et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 40, 1231-1236 (1999).
36. Samren EB, van Duijn CM, Christiaens GCML, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol. 46(5), 739-746 (1999).
37. Sabers A, Dam M, a-Rogvi-Hansen B et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta. Neurol. Scand. 109, 9-13 (2004).
38. Kaneko S, Battino D, Andermann E et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 33, 145-158 (1999).
39. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 60, 575-579 (2003).
40. Lowe SA. Drugs in pregnancy. Anticonvulsants and drugs for neurological disease. Best Pract. Res. Clin. Obstet. Gynaecol. 15(6), 863-876 (2001).
41. Holmes LB, Wyszynski DF. North American antiepileptic drug pregnancy registry. Epilepsia 45(11), 1465 (2004).
42. Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Registry. J. Neurol. Neurosurg. Psychiatry 77, 193-198 (2006).
43. Artama M, Auvinen A, Raudaskoski T, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64, 1874-1878 (2005).
44. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based study. Acta Pediatr. 93, 174-176 (2004).
45. Meador KJ, Loring DW, Baker G et al, NEAD Study Group. Differential and dose dependent effects of in utero antiepileptic drugs. Neurology 64(Suppl. 1), A427 (2005).
46. Barrett C, Richens A. Epilepsy and pregnancy: report of an epilepsy research foundation workshop. Epilepsy Res. 42, 147-187 (2003).
47. Samren EB, van Duijn DM, Koch S et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38(9), 981-990 (1997).
48. Dean JCS, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J. Med. Genet. 39, 251-259 (2002).
49. Christianson AL, Chesler N, Kromberg JGR. Fetal valproate syndrome: clinical and neurodevelopmental features in two sibling pairs. Dev. Med. Child Neurol. 36(4), 361-369 (1994).
50. Wyszynski DF, Nambisan M, Surve T et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64, 961-915 (2005).
51. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 42(Suppl. 5), 17-24 (1992).
52. Bennett GD, Wlodarczyk B, Calvin JA, Craig JC, Finnell RH. Valproic acidinduced alterations in growth and neurotrophic factor. Reprod. Toxicol. 14, 1-11 (2000).
53. Duncan S, Mercho S, Lopes-Cendes I et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 42(6), 750-753 (2001).
54. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry 70(1), 15-21 (2001).
55. Holmes LB, Wyszynski DF, Lieberman E, AED Pregnancy Registry. The AED (antiepileptic drug) Pregnancy Registry: a 6 year experience. Arch. Neurol. 61, 673-678 (2004).
56. Reinisch JM, Sanders SA, Mortenson EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 274, 1518-1525 (1995).
57. Adams J, Harvey EA, Holmes LB. Cognitive deficits following gestational monotherapy with phenobarbital and carbamazepine. Neurotoxicol. Teratol. 22, 466-467 (2000).
58. Oguni M, Osawa M. Epilepsy and pregnancy. Epilepsia 45(Suppl. 8), 37-41 (2004).
59. Lindhout D, Omtzigt JG. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 35(Suppl. 4), S19-S28 (1994).
60. Gaily E, Kantola-Sorsa E, Hiilesmaa V. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62(1), 28-32 (2004).
61. Cunnington M, Tennis P, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 64, 955-960 (2005).
62. Holmes LB, Wyszynski DF, Baldwin EJ, Haebecker E, Glassman LH, Smith CR. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. Birth Defects Res. Part A Clin. Mol. Teratol. 76(5), 318A (2006).
63. Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 62(2), 292-295 (2004).
64. de Haan GJ, Edelbroek P, Segers J et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 63, 571-573 (2004).
65. Mazzucchelli I, Onat FY, Ozkara C et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 47(3), 504-509 (2006).
66. Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr. Med. Res. Opin. 21(5), 693-701 (2005).
67. Meischenguiser R, D'Giano CH, Ferraro SM. Oxcarbazeine n pregnancy: clinical experience in Argentina. Epilepsy Behav. 5, 163-167 (2004).
68. Montouris G. Gabapentin exposure in human pregnancy: results from the gabapentin pregnancy registry. Epilepsy Behav. 4, 310-317 (2003).
69. Kuzniecky RI, Mortati K. Practical strategies for switching to newer antiepileptic drugs. Rev. Neurol. Dis. 2(4), 186-198 (2005).
70. ten Berg K. Samren EB, van Oppen AC et al. Leviteracetam use and pregnancy outcome. Reprod. Toxicol. 20, 175-178 (2005).
71. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 37, 1242-1244 (1996).
72. Tomson T, Battino D. Teratogenicity of antiepileptic drugs: state of the art. Curr. Opin. Neurol. 18, 135-140 (2005).
73. Pschirrer ER. Seizure disorders in pregnancy. Obstet. Gynecol. Clin. North Am. 31(2), 373-384 (2004).
74. Jager-Roman E, Deichl A, Jakob S et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J. Pediatr. 108(6), 997-1004 (1986).
75. Koch S, Jager-Roman E, Losche G, Nau H, Rating D, Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta. Pediatr 84, 739-746 (1996).
76. Meador KJ. Cognitive effects of epilepsy and of antiepileptic medications. In: The Treatment of Epilepsy. Principles and Practices, 4th Edition. Wyllie E (Ed). Lippincott Williams & Wilkins, PA, USA, 1215-1226 (2005).
77. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenges of treating epilepsy in pregnancy. Epilepsia 45, 1171-1175 (2004).
78. Williams J, Myson V, Steward SF. Selfdiscontinuation of antiepileptic medication in pregnancy: detection by hair analysis. Epilepsia 43, 824-831 (2002).